Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCX872-B and SBRT in resectable pancreatic cancer
NCT03778879Phase 2Withdrawn
- Start
- Aug 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ccx872-b in pancreatic adenocarcinoma (PDAC). Planned start Aug 2019; status: withdrawn.
02
Drugs
ccx872-b
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03778879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778879.